Company intelligence / Profile preview
Organicell Regenerative Medicine
Miami, Florida, United Statesorganicell.com ↗
- Ownership
- Public · BPSR
- Employees
- ~50
- Development stage
- Other
01
Overview
Organicell's lead product Zofin™ has received FDA approval for 18 eINDs and four Phase I/II randomized, placebo-controlled trials for COVID-19, COPD, Osteoarthritis, and COVID Long Haulers. An Expanded Access trial for Mild to Moderate COVID-19 was completed and published in December 2021. No severe adverse events have been reported with Zofin™. The company is planning to launch Phase II trials for Zofin™ in 2025.
- Therapeutic areas
- PulmonologyEndocrinologyRheumatologyNeurologyInfectious Diseases
- Modalities
- ExosomesExtracellular vesiclesMicroRNAsBiologic therapeutics
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Regenerative Care Network
Beyond the preview
Go deeper on Organicell Regenerative Medicine.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Organicell Regenerative Medicine.